WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016104964) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE SURFACE DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/104964    International Application No.:    PCT/KR2015/012707
Publication Date: 30.06.2016 International Filing Date: 25.11.2015
IPC:
C07K 7/06 (2006.01), A61K 38/08 (2006.01)
Applicants: EYEBIO KOREA [KR/KR]; (Eobang-dong) F-1010, 197, Inje-ro Gimhae-si Gyeongsangnam-do 50834 (KR)
Inventors: YANG, Jae Wook; (KR).
LEE, Hye Sook; (KR).
LEE, Ji Hyun; (KR).
LEE, Yoon Jin; (KR)
Agent: TAEBAEK INTELLECTUAL PROPERTY LAW FIRM; #601 Innoplex 1 cha, 151Gasandigital 1-ro Geumcheon-gu Seoul 08506 (KR)
Priority Data:
10-2014-0190726 26.12.2014 KR
Title (EN) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE SURFACE DISEASES
(FR) COMPOSITION PHARMACEUTIQUE DESTINÉE À PRÉVENIR OU À TRAITER LES MALADIES SUPERFICIELLES DE L’ŒIL
(KO) 안구 표면 질환 예방 또는 치료용 약학조성물
Abstract: front page image
(EN)The present invention relates to a pharmaceutical composition for preventing or treating eye surface diseases, the composition containing, as an active ingredient, peptide GQDGLAGPK on the basis of collagen type II α1, isolated from the chondrocyte-derived extracellular matrix. In an alkali burn animal model treated with the peptide GQDGLAGPK, the corneal opacity was reduced and the expression of CD31 and VEGF, which are angiogenesis factors, was reduced. In addition, macrophages, TNFα, ICAM-1, VCAM-1, and MMP-9, which are inflammation markers, were reduced, and the expression of NF-κB, which is an inflammation-inducing factor, was reduced. Therefore, the peptide GQDGLAGPK of the present invention can be used as a pharmaceutical composition for preventing or treating corneal diseases, which are eye surface diseases.
(FR)La présente invention concerne une composition pharmaceutique destinée à prévenir ou à traiter des maladies superficielles de l’œil, la composition contenant, à titre de principe actif, le peptide GQDGLAGPK basé sur le collagène de type II α1, isolé à partir de la matrice extracellulaire dérivée des chondrocytes. Dans un modèle animal de brûlure par un alcali traité avec le peptide GQDGLAGPK, l'opacité de la cornée a été réduite et l'expression de CD31 et du VEGF, qui sont des facteurs d'angiogenèse, a été réduite. De plus, les macrophages, le TNF-α, l'ICAM-1, le VCAM-1, et le MMP-9, qui sont des marqueurs d'inflammation, ont été réduits, et l'expression du NF-κB, qui est un facteur d'induction de l'inflammation, a été réduite. Par conséquent, le peptide GQDGLAGPK selon l'invention peut être utilisé à titre de composition pharmaceutique pour prévenir ou traiter les maladies de la cornée, qui sont des maladies superficielles de l’œil.
(KO)본 발명은 연골세포 유래 세포외 기질에서 분리된 콜라겐 타입 II α1 기반의 펩타이드 GQDGLAGPK를 유효성분으로 함유하는 안구 표면 질환 예방 또는 치료용 약학조성물에 관한 것으로, 펩타이드 GQDGLAGPK를 처리한 알칼리 화상 동물 모델의 경우, 각막 혼탁이 감소하였으며, 혈관신생 인자인 CD31 및 VEGF 발현이 감소되었다. 또한, 염증 마커인 대식세포, TNFα, ICAM-1, VCAM-1 및 MMP-9이 감소하였으며, 염증 유발 인자인 NF-κB의 발현이 억제되었다. 따라서, 본 발명의 펩타이드 GQDGLAGPK는 안구 표면 질환인 각막 질환의 예방 또는 치료용 약학조성물로 사용될 수 있다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)